Advertisement

Topics

FDA OKs Patisiran (Onpattro) for Polyneuropathy in hAATR

10:49 EDT 10 Aug 2018 | Medscape

Patisiran is the first FDA-approved treatment for polyneuropathy caused by hATTR and the first RNA-based therapy to treat a rare disease.
FDA Approvals

Original Article: FDA OKs Patisiran (Onpattro) for Polyneuropathy in hAATR

NEXT ARTICLE

More From BioPortfolio on "FDA OKs Patisiran (Onpattro) for Polyneuropathy in hAATR"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...